Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENDYMION 2 long-term extension study of soticlestat in Dravet syndrome or Lennox-Gastaut syndrome
2021-002482-17Phase 3Active
- Sponsor
- Takeda
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of soticlestat in Dravet syndrome and Lennox-Gastaut syndrome (LGS) (2 cohorts), sponsored by Takeda. Primary endpoint: Incidence of treatment-emergent adverse events. Started Dec 2021; status: active.
02
Drugs
soticlestat
03
Conditions
Dravet syndromeLennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on 2021-002482-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002482-17.